4.8 Article

CD40-Mediated Activation of Chronic Lymphocytic Leukemia Cells Promotes Their CD44-Dependent Adhesion to Hyaluronan and Restricts CCL21-Induced Motility

期刊

CANCER RESEARCH
卷 73, 期 2, 页码 561-570

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-2749

关键词

-

类别

资金

  1. Austrian Science Fund FWF [W1213, SFB P021, P25015-B13]
  2. Austrian National Bank [13420, 14311]
  3. Paracelsus Medical University Salzburg [E-10/11/058-HAR]
  4. Klinische Malignom- und Zytokinforschung Salzburg-Innsbruck GmbH
  5. province of Salzburg
  6. Austrian Science Fund (FWF) [P 25015] Funding Source: researchfish
  7. Austrian Science Fund (FWF) [P25015] Funding Source: Austrian Science Fund (FWF)

向作者/读者索取更多资源

Microenvironmental interactions are crucial for the survival and proliferation of chronic lymphocytic leukemia (CLL) cells. CD4+ T cells that express CD40 ligand (CD40L), along with other accessory immune and stromal cells within CLL lymph nodes, provide signals needed for activation and outgrowth of the tumor clone. Furthermore, correct positioning of CLL cells within lymphoid subcompartments is essential for the transmission of these supportive signals. Thereby, interstitial cell migration and adhesion events, influenced by activational stimuli, determine CLL cell localization. CD44 has been implicated in cell activation, migration, and tissue retention via binding to its extracellular matrix ligand hyaluronan (HA). In this study, we investigated the role of CD44-HA interactions for CLL positioning and interaction with supportive microenvironments in peripheral lymph nodes, focusing on its regulation via CD40L-dependent, T-cell-mediated activation of CLL cells. We found that hyaluronan triggered a robust CCL21-induced motility of resting CLL cells. However, CD40L stimulation promoted the firm, CD44-mediated adhesion of CLL cells to hyaluronan, antagonizing their motile behavior. N-linked glycosylations of CD44, particularly associated with the variant isoform CD44v6 after CD40L activation, seemed to facilitate hyaluronan recognition by CD44. We propose that the CD40L-CD40 signaling axis provides a stop signal to motile CLL cells within lymph node compartments by inducing high avidity CD44-HA adhesion. This might retain CLL cells close to T-cell stimuli and facilitate essential interactions with hyaluronan-bearing stromal cells, collectively promoting CLL cell proliferation and survival. Cancer Res; 73(2); 561-70. (C) 2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol

Florian Huemer, Stefan Hecht, Bernhard Scharinger, Verena Schlintl, Gabriel Rinnerthaler, Konstantin Schlick, Ronald Heregger, Thomas Melchardt, Angela Wimmer, Iris Muehlbacher, Oliver Owen Koch, Daniel Neureiter, Eckhard Klieser, Sara Seyedinia, Mohsen Beheshti, Richard Greil, Lukas Weiss

Summary: This study investigated the impact of body composition parameters and dynamics on clinical outcomes in gastric/GEJ cancer patients undergoing perioperative FLOT chemotherapy. The study found that the skeletal muscle index (SMI) was the only body composition parameter that significantly decreased during pre-operative FLOT. Pre-FLOT BMI and SMI were significantly associated with progression-free survival (PFS) in multivariable analysis.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Hematology

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study

Olga Oleshko, Sonja Werwitzke, Annika Klingberg, Torsten Witte, Hermann Eichler, Robert Klamroth, Katharina Holstein, Christina Hart, Christian Pfrepper, Paul Knoebl, Richard Greil, Peter Neumeister, Birgit M. Reipert, Andreas Tiede

Summary: The root cause of autoantibody formation against FVIII in AHA is unclear. A diverse pattern of autoantibodies is associated with AHA, suggesting a more general breakdown of immune tolerance might be involved in its pathology.

BLOOD ADVANCES (2023)

Article Oncology

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin

Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancerdresults from an international, multicenter analysis coordinated by the AGMT Study Group

S. P. Gampenrieder, V. Dezentje, M. Lambertini, A. de Nonneville, M. Marhold, F. Le Du, A. Cortes Salgado, D. Alpuim Costa, M. Vaz Batista, N. Chic Ruche, C. Tinchon, A. Petzer, E. Blondeaux, L. Del Mastro, G. Targato, F. Bertucci, A. Goncalves, F. Viret, R. Bartsch, C. Mannsbart, A. Deleuze, L. Robert, C. Saavedra Serrano, M. Gion Cortes, M. Sampaio-Alves, M. Vitorino, L. Pecen, C. Singer, N. Harbeck, G. Rinnerthaler, R. Greil

Summary: Based on a large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%, but it showed no significant impact on overall survival (OS).

ESMO OPEN (2023)

Review Oncology

How I treat diffuse large B-cell lymphoma

T. Melchardt, A. Egle, R. Greil

ESMO OPEN (2023)

Article Oncology

Barriers to patient access of CAR T cell therapies in Austria

Georg Hopfinger, Bernhard Rupp, Richard Greil

Summary: Chimeric antigen receptor (CAR) T cell therapies have the potential to be an effective treatment option for B cell malignancies, particularly relapsed or refractory diffuse large B cell lymphoma (DLBCL). However, despite being available in wealthy Western countries, patient access to CAR-T therapy can be limited due to systemic barriers. In Austria, a significant percentage of eligible DLBCL patients did not receive CAR-T therapy in 2021, raising concerns about accessibility. This report identifies barriers to access and provides recommendations for systemic solutions to improve CAR-T access in Austria.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2023)

Article Hematology

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles

Summary: The RE-MIND2 study compared the patient outcomes of tafasitamab+lenalidomide with other therapies for relapsed/refractory DLBCL. The data showed that tafasitamab+lenalidomide had better overall survival rates compared to polatuzumab vedotin+bendamustine+rituximab and rituximab+lenalidomide.

ANNALS OF HEMATOLOGY (2023)

Article Oncology

Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer

Sandro. M. Wagner, Teresa Magnes, Thomas Melchardt, Dominik Kiem, Lukas Weiss, Daniel Neureiter, Christina Wagner, Marie-Bernadette Aretin, Stefan Nemec, Gabriele Gamerith, Georg Pall, Richard Greil, Thorsten Fuereder

Summary: This study evaluated the efficacy and safety of immune checkpoint inhibitor therapy in unselected patients with SCCHN. The results showed that CPI therapy alone or in combination with chemotherapy is an effective treatment for SCCHN patients, consistent with previous studies.

ANTICANCER RESEARCH (2023)

Article Biochemical Research Methods

Validation of genetic variants from NGS data using deep convolutional neural networks

Marc Vaisband, Maria Schubert, Franz Josef Gassner, Roland Geisberger, Richard Greil, Nadja Zaborsky, Jan Hasenauer

Summary: Accurate somatic variant calling from next-generation sequencing data is crucial for personalised cancer therapy. A machine learning approach using a Convolutional Neural Network can improve the validation of genetic variants, incorporating contextual data from sequencing tracks. This model performs on par with trained researchers and enhances reproducibility and scalability.

BMC BIOINFORMATICS (2023)

Article Oncology

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinomaefinal results of the randomized AIO MATEO phase II trial

G. Stocker, S. Lorenzen, T. Ettrich, A. -l. Herz, F. Longo, A. Kiani, M. Venerito, J. Trojan, R. Mahlberg, N. Moosmann, B. Chibaudel, S. Kubicka, R. Greil, S. Daum, M. Geissler, J. Larcher-Senn, G. Keller, F. Lordick, G. M. Haag

Summary: S-1 maintenance therapy following platinum-based induction therapy leads to non-inferior survival outcomes compared with the continuation of platinum-based combination chemotherapy. It also has fewer adverse effects and supports the use of a fluoropyrimidine maintenance strategy. These findings challenge the practice of continuing platinum combination chemotherapy after 3 months of induction therapy in patients with advanced HER2-negative esophagogastric adenocarcinoma.

ESMO OPEN (2023)

Review Pharmacology & Pharmacy

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial

Noemie Mercier, Drifa Belhadi, Aline DeChanet, Christelle Delmas, Juliette Saillard, Marina Dumousseaux, Soizic Le Mestre, Claire Fougerou-Leurent, Assia Ferrane, Charles Burdet, Helene Esperou, Florence Ader, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Claire Andrejak, Jose Artur Paiva, Evelina Tacconelli, Therese Staub, Richard Greil, Dominique Costagliola, France Mentre, Yazdan Yazdanpanah, Alpha Diallo

Summary: This article presents the challenges faced by an academic Safety Department in managing the safety of a European trial during the COVID-19 pandemic. The trial involved repurposed and investigational drugs for hospitalized COVID-19 patients. The high number of Serious Adverse Events (SAEs) made it difficult to evaluate and identify potential safety signals.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2023)

Correction Hematology

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (vol 102, pg 1773, 2023)

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles

ANNALS OF HEMATOLOGY (2023)

Meeting Abstract Oncology

Management of metastatic colorectal cancer in patients >= 70 years: A single-center experience

F. Huemer, C. Dunkl, G. Rinnerthaler, K. Schlick, R. Heregger, K. Emmanuel, D. Neureiter, E. Klieser, M. Deutschmann, F. Roeder, R. Greil, L. Weiss

ANNALS OF ONCOLOGY (2023)

Article Oncology

Management of metastatic colorectal cancer in patients & GE;70 years-a single center experience

Florian Huemer, Celine Dunkl, Gabriel Rinnerthaler, Konstantin Schlick, Ronald Heregger, Klaus Emmanuel, Daniel Neureiter, Eckhard Klieser, Michael Deutschmann, Falk Roeder, Richard Greil, Lukas Weiss

Summary: This retrospective analysis characterized elderly patients (70 years and older) with metastatic colorectal cancer (mCRC) undergoing systemic therapy. The median overall survival (OS) was 25.6 months. First-line anti-EGFR-based therapy showed a trend towards longer OS compared to anti-VEGF-based therapy or chemotherapy alone in left-sided mCRC. Metastasectomy and/or local ablative treatment with curative intent were associated with improved OS.

FRONTIERS IN ONCOLOGY (2023)

Meeting Abstract Oncology

Prognosis and treatment landscape of HER2-positive metastatic breast cancer (MBC) before the availability of tucatinib and trastuzumab-deruxtecan: Results from the Austrian AGMT_MBC-Registry

Simon P. Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Margit Sandholzer, August F. Zabernigg, Daniel Egle, Christopher Hager, Petra Pichler, Florian Roitner, Johannes Andel, Kathrin Strasser-Weippl, Michael Knauer, Michael Hubalek, Christian F. Singer, Richard Greil

CANCER RESEARCH (2023)

暂无数据